Popular Trials
Amino Acid Derivative
IB1001 for Ataxia
This trial will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T). There are two phases to the study: the Parent Study and the Extension Phase. The Parent Study will evaluate the short-term safety and efficacy of IB1001, while the Extension Phase will assess the long-term safety and efficacy of IB1001.
Behavioural Intervention
Rehabilitation Program for Spastic Ataxia
This trial aims to evaluate the effectiveness of a 12-week rehabilitation program called IMPACT on individuals with spastic ataxias. Spastic ataxias are diseases that cause walking difficulties and balance issues
Popular Filters
Trials for Friedreich Ataxia Patients
Nrf2 Activator
Omaveloxolone for Friedreich's Ataxia
This trial is testing omaveloxolone, a drug that may help people with Friedreich's ataxia by boosting their body's natural defenses against cell damage. The study focuses on patients with this genetic condition because they have weakened antioxidant systems. Omaveloxolone works by activating a protein that helps protect cells from damage. It aims to improve cell function and reduce harmful effects in people with Friedreich's ataxia.
Quinone Analog
Vatiquinone for Friedreich Ataxia
This trial is testing the long-term safety and effectiveness of vatiquinone in people with Friedreich ataxia who have already used this medication. The goal is to ensure it remains safe and helpful over an extended period. Idebenone, a predecessor to vatiquinone, has been used in Friedreich's ataxia patients and shown positive effects on cardiac hypertrophy.
Gene Therapy
Gene Therapy for Cardiomyopathy in Friedreich's Ataxia
This trial will test a new gene therapy for Friedreich's Ataxia, a rare degenerative disease. The therapy will be delivered intravenously and will be evaluated for safety and efficacy over a 5 year period.
Gene Therapy
Gene Therapy for Cardiomyopathy in Friedreich's Ataxia
This trial is testing a gene therapy to treat Friedreich's ataxia, a disease that affects the heart. The therapy uses a virus to deliver the gene. It will be given intravenously to 10 people to see if it is safe and effective.
Trials for FA Patients
Nrf2 Activator
Omaveloxolone for Friedreich's Ataxia
This trial is testing omaveloxolone, a drug that may help people with Friedreich's ataxia by boosting their body's natural defenses against cell damage. The study focuses on patients with this genetic condition because they have weakened antioxidant systems. Omaveloxolone works by activating a protein that helps protect cells from damage. It aims to improve cell function and reduce harmful effects in people with Friedreich's ataxia.
Quinone Analog
Vatiquinone for Friedreich Ataxia
This trial is testing the long-term safety and effectiveness of vatiquinone in people with Friedreich ataxia who have already used this medication. The goal is to ensure it remains safe and helpful over an extended period. Idebenone, a predecessor to vatiquinone, has been used in Friedreich's ataxia patients and shown positive effects on cardiac hypertrophy.
Gene Therapy
Gene Therapy for Cardiomyopathy in Friedreich's Ataxia
This trial will test a new gene therapy for Friedreich's Ataxia, a rare degenerative disease. The therapy will be delivered intravenously and will be evaluated for safety and efficacy over a 5 year period.
Gene Therapy
Gene Therapy for Cardiomyopathy in Friedreich's Ataxia
This trial is testing a gene therapy to treat Friedreich's ataxia, a disease that affects the heart. The therapy uses a virus to deliver the gene. It will be given intravenously to 10 people to see if it is safe and effective.
Phase 3 Trials
Investigational Drug for Spinocerebellar Ataxia
This trial tests a sugar solution injection called trehalose to help adults with a condition affecting coordination and balance. The treatment aims to protect nerve cells and improve symptoms. Trehalose, also known as SLS-005, is being investigated in various regimens for its potential neuroprotective effects.
Glutamate Modulator
Troriluzole for Spinocerebellar Ataxia
This trial is testing whether a medication called Troriluzole can help people with spinocerebellar ataxia by balancing a brain chemical to prevent damage. Troriluzole is related to riluzole, which has been shown to prolong survival and slow functional deterioration in patients with ALS.
Quinone Analog
Vatiquinone for Friedreich Ataxia
This trial is testing the long-term safety and effectiveness of vatiquinone in people with Friedreich ataxia who have already used this medication. The goal is to ensure it remains safe and helpful over an extended period. Idebenone, a predecessor to vatiquinone, has been used in Friedreich's ataxia patients and shown positive effects on cardiac hypertrophy.
Pro-Drug
BHV-4157 for Ataxia
This trial tests BHV-4157, a drug that turns into riluzole in the body, on adults with cerebellar ataxia. The drug helps protect nerve cells and may improve coordination and balance. Riluzole has been shown to prolong survival and slow functional deterioration in patients with ALS.
Trials With No Placebo
Noninvasive Brain Stimulation
Transcranial Pulsed Current Stimulation for Ataxia
This trial is testing a method that uses small electrical currents sent through scalp electrodes on patients with neurodegenerative ataxia. These patients have severe balance, speech, and coordination problems. The goal is to see if the electrical currents can improve their brain and nerve function.
Non-invasive Brain Stimulation
TMS for Cerebellar Ataxia
This trial aims to see if brain activity can predict and improve motor learning in people with cerebellar ataxia. It uses non-invasive brain stimulation to adjust brain activity and tests if this helps patients learn new movement skills better.
Behavioral Intervention
Physical Activity Coaching for Ataxia
This trial will test whether a physical activity coaching program can help people with cerebellar ataxia increase their physical activity. The program will use a physical or occupational therapist to provide up to five one-on-one coaching sessions for newly diagnosed individuals. Participants will be assessed twice, three months apart, and will receive coaching interventions via Zoom healthcare platform.
Behavioral Intervention
Exercise Therapy for Cerebellar Ataxia
This trial will use neuroimaging techniques to study the effects of balance and aerobic training on the brain, specifically the degenerating cerebellum. The hypothesis is that balance training impacts structures outside the cerebellum while aerobic training affects the cerebellum itself.
Behavioral Intervention
Visual Feedback Reach Training for Ataxia
This trial compares two training methods to improve arm movements in people with cerebellar ataxia. It targets individuals who struggle with movement coordination due to cerebellum damage. The methods involve practicing reaching movements with feedback to enhance coordination.
Frequently Asked Questions
Introduction to cerebellar ataxia
What are the top hospitals conducting cerebellar ataxia research?
In the realm of cerebellar ataxia, several top hospitals are leading the charge in clinical trials and groundbreaking research. The University of South Florida in Tampa is taking a prominent role with six active trials focused on this condition, along with an impressive total of 18 previous studies. Since their first recorded cerebellar ataxia trial back in 2009, this institution has been dedicated to advancing our understanding and treatment options for individuals affected by this neurological disorder.
On the West Coast, UCLA in Los Angeles is also making significant strides in the fight against cerebellar ataxia. With four ongoing trials and six completed studies since initiating their first trial in 2015, UCLA's commitment to exploring innovative approaches to tackle this condition is evident.
Further east, Johns Hopkins University School of Medicine located in Baltimore may have only two active cerebellar ataxia trials currently underway but they are contributing to vital research efforts. Interestingly enough, they conducted their very first trial on cerebellar ataxia as recently as 2022 – a testament to how rapidly medical progress can be achieved.
Meanwhile Northwestern University in Chicago joins forces with two current clinical investigations targeting cerebellar ataxia while sharing similar historical significance: conducting its pioneering study regarding these disorders commencing from2016.The University of Chicago also based within Chi-town landscape adds up significantly through it's present-day dedication housing two active tests for cerabellum irregularity; furthermore contributing towards various experiments summing upto four that paved way over last decade starting from capturing initial associated case into account during preliminary investigation beginning from years ago lasting until2010
These esteemed institutions showcase not just their expertise but also unwavering commitment toward improving the lives of individuals afflicted by cerebellar ataxia. By pushing boundaries and seeking breakthroughs through clinical trials across different locations including Tampa Bay ,Los Angeles,Baltimore,and Chicago - researchers strive tirelessly towards finding effective treatments and ultimately a cure for this debilitating neurological condition.
Which are the best cities for cerebellar ataxia clinical trials?
When it comes to cerebellar ataxia clinical trials, several cities offer promising opportunities for research and treatment development. Los Angeles, California stands out with 8 active trials focusing on IB1001, troriluzole, and other potential interventions. New york, New York follows closely behind with 7 ongoing studies exploring aerobic training, troriluzole, and more. Tampa, Florida also shows promise with 7 active trials investigating troriluzole and IVIG among other treatments. Philadelphia, Pennsylvania contributes to the advancement of care through 7 studies involving vatiquinone and omaveloxolone capsules. Finally, Boston Massachusetts offers 5 active trials studying troriluzole and SLS-005 in an effort to improve outcomes for individuals with cerebellar ataxia.
Which are the top treatments for cerebellar ataxia being explored in clinical trials?
Exciting developments are underway in the exploration of treatments for cerebellar ataxia. Leading the charge is vatiquinone, currently involved in two active trials and three all-time cerebellar ataxia trials since its listing in 2020. Another promising avenue being explored is transcranial magnetic stimulation (TMS), with one active trial and two all-time cerebellar ataxia trials recorded since 2016. Additionally, aerobic training shows potential as a treatment option, with one ongoing trial among its two all-time cerebellar ataxia trials listed from 2020 onwards. These innovative approaches offer hope to those affected by this challenging neurological condition.
What are the most recent clinical trials for cerebellar ataxia?
Recent clinical trials offer new hope for individuals with cerebellar ataxia, a debilitating condition affecting coordination and movement. Among these trials is the exploration of vatiquinone as a potential treatment, which has progressed to Phase 3 after showing promising results in earlier phases. Additionally, CTI-160l and SLS-005 are being investigated in Phase 2 and Phase 3 studies respectively, aiming to assess their effectiveness in managing cerebellar ataxia symptoms. Another promising avenue is the use of high-dose LX2006, currently undergoing combined Phase 1 and Phase 2 testing. As these trials continue to advance our understanding of this complex disorder, we move closer towards finding effective therapies that can improve the quality of life for those affected by cerebellar ataxia.
What cerebellar ataxia clinical trials were recently completed?
In the realm of cerebellar ataxia, a notable clinical trial recently concluded, shedding light on potential advancements in treatment. Design Therapeutics sponsored a trial investigating DT-216 and successfully completed it in March 2022. This study's completion signals progress towards tackling the challenges associated with cerebellar ataxia, offering hope for improved therapies for individuals affected by this debilitating condition.